Citation Tools

Download PDFPDF

Original research
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

Download to a citation manager

Cite this article as:
Naing A, Gainor JF, Gelderblom H, et al
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors